Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Pharma Safety Bureau Seeks 246 Million Yen to Shake Off Public Distrust in Generics: FY2022 Budget Request
August 27, 2021
- MHLW Won’t Recall Moderna Vaccine Vials for Now
August 26, 2021
- Japan Approves Forxiga for CKD, Rinvoq’s Atopic Dermatitis Use and More
August 26, 2021
- Trade Groups Urges New Reimbursement Fee Evaluation for SaMD
August 26, 2021
- Takeda’s Pevonedistat Gets 1st Sakigake Tag under PMD Law
August 26, 2021
- COVID-19 Antibody Cocktail to Be Made Available for Outpatients Too: Minister
August 25, 2021
- Orphan Status Granted to Fenfluramine, Asciminib, Vosoritide
August 25, 2021
- Pharma Leaders Support Draft Industry Vision, but Stress Need for Price Maintenance of Patented Meds: Confab
August 25, 2021
- PAFSC to Review Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug and More
August 24, 2021
- Takeda’s 1st Cell Therapy Up for PAFSC Review on Sept. 6
August 24, 2021
- MHLW to Seek Budget to Boost GMP Inspections to Secure Trust in Generics: FY2022 Request
August 23, 2021
- New Pharma Vision to Set Out Clear Goal, KPIs after Lawmaker Calls
August 23, 2021
- Sharp Drop in Suspected Violations Seen in FY2020 Drug Promotion, but Comparison Difficult due to COVID-19: MHLW
August 23, 2021
- MHLW’s FY2022 Budget Request to Focus on COVID-19 R&D, Quality Generic System
August 20, 2021
- Japan Panel OKs COVID-19 Vaccine Health Damage Claims for First Time
August 20, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
- Public-Private Dialogue for New Pharma Vision Set for Aug. 24
August 18, 2021
- Otsuka’s Eczema Med, Alexion’s Blood Thinner Antidote Up for PAFSC Review on Aug. 30
August 17, 2021
- 14 Firms Flock to Get Approval for E Keppra Generics towards December Listing
August 17, 2021
- MHLW OKs Ronapreve Use in Short-Term Hospitalization and at Accommodation Facilities
August 17, 2021
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…